Drug Database
DI

diphtheria vaccine

✓ Approved

Changchun Institute · Vaccine · Vaccine

What is diphtheria vaccine?

diphtheria vaccine is a vaccine developed by Changchun Institute. It is approved for therapeutic indications via injectable (others).

Drug Profile

CompanyChangchun Institute
Drug ClassVaccine
RouteInjectable (Others)
StatusApproved

Therapeutic Indications

diphtheria vaccine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsDiphtheria✓ Approved

Related Research Articles

PubMedbioRxiv : the preprint server for biology2026-07-17

Exposure to P. falciparum and common cold viruses shape vaccine responses in early life.

Bach Florian F, Sigal George G, Wohlstadter Jacob J, Brown Rayven R et al.

Vaccine immunogenicity is consistently lower in low-income countries than in high-income settings, yet the factors driving this disparity remain incompletely understood. Using multiplexed electrochemiluminescence serology, we measured IgG and IgA responses to Expanded Program on Immunization (EPI) vaccines and common childhood viral infections in 89 Ugandan infants. We integrated detailed parasitological surveillance and maternal clinical data to examine how P. falciparum infection history, concurrent parasitemia, maternal gravidity, and early-life viral exposures shaped serological profiles. We found that infants mounted robust responses to most EPI vaccines, but critical gaps in protection persisted for diphtheria, measles and rubella. Children born to primigravid mothers had lower antibody levels at 8 weeks of age, independent of placental malaria and only partially explained by maternal age. Contrary to expectation, cumulative P. falciparum exposure was positively associated with antibody concentrations to diphtheria and varicella, and concurrent parasitemia was positively correlated with responses to multiple antigens. Seroconversion to rhinovirus C was associated with higher IgG and IgA levels to several vaccines. Together, these findings suggest that common microbial exposures during infancy, including respiratory viruses and P. falciparum may positively modulate vaccine responsiveness.

PubMedFrontiers in public health2026-07-17

A cross-sectional study of seroprevalence in Armenia, 2025: measles, mumps, rubella, and diphtheria.

Popova A Y AY, Smirnov V S VS, Egorova S A SA, Atoyan S A SA et al.

Prevention and control of vaccine-preventable infections is a key component of maintaining public health, and the overall state of immunity is the determining factor. To study herd immunity of the Armenian population to measles, rubella, mumps, and diphtheria. The study involved 5,513 individuals from all regions aged from 1 year and above. A cohort of volunteers, stratified into 9 age groups, was formed including by region and activity using a web application. For each infection, the presence and/or levels of immunoglobulin G were determined by the enzyme immunoassay method using Russian-made test systems. The cohort average seroprevalence values for measles, rubella, mumps, and diphtheria were 88.3%, 97.2, 83.2, and 56.3%, respectively. The least protected age groups were: children <5 years (80.7% seropositive) and adults 30-49 years (82-83%) regarding measles; adolescents and adults <49 years (73-79%) regarding mumps; and the older adults (34.4%) regarding diphtheria. Most volunteers had: low or moderate measles Ab levels (0.18-1 IU/mL); high levels of rubella Abs (>200 IU/mL); and a basic protective level of diphtheria toxin Abs (0.1-1 IU/mL). With age, a trend is seen: seropositivity for the viral pathogens (measles, mumps, and rubella) increased to maximum values; and diphtheria seropositivity decreased to minimum values. The level of herd immunity in Armenia is sufficient only for rubella, as confirmed by the absence of cases. Currently, immunity to measles and mumps is present, which prevents outbreaks but may not be fully preventive of sporadic cases. Despite the absence of diphtheria, insufficient protection in older adults makes them a risk group for incidence and severity. However, immunity levels in our study were assessed based only on humoral immunity, which may underrepresent the full immunological response, including that mediated by cellular immunity.

PubMedThe Pan African medical journal2026-07-17

Factors associated with outbreak of diphtheria in Kafanchan, Kaduna State, Nigeria: July-October 2023.

Okhuarobo Uwaifiokun Julius UJ, Abbah Okpachi Christopher OC, Owoicho Samuel Amifofum SA, Okon Ubong Akpan UA et al.

The year 2023 witnessed the re-emergence of diphtheria in Nigeria. Kafanchan, Kaduna State, reported an unusual surge in cases and deaths. We investigated the outbreak to identify associated risk factors of the disease. We conducted an unmatched (1:2) case-control study. Case-patients were identified through the State linelist and traced to their residence. At the same time, controls were randomly selected from neighbors without symptoms or signs suggestive of diphtheria within the same community. Data was collected using an interviewer-administered structured questionnaire. Bivariate analysis was done to ascertain the odds ratio (OR), while multivariate logistic regression analysis was done to calculate the adjusted odds ratio (aOR). The confidence interval (CI) was set at 95%. A total of 91 case-patients and 182 controls were recruited. The median age of case-patients was 7 years (5-10 years). Forty (44%) of 91 case-patients were females. Sixty-four (70%) of 91 case-patients were from Kafanchan ward B, and the case fatality rate was 23%. Exposure to pentavalent vaccination was found to be associated with protection from diphtheria (aOR: 0.39, 95% CI: 0.20-0.77). Thirty-one (34.07%) of 91 case-patients had contact with someone with respiratory symptoms [OR = 37.2; 95% CI = 16.8-82.6; p <0.001]. Thirty-seven (40.66%) of 91 case-patients had contact with a confirmed case [OR = 25.1; 95% CI = 11.7-53.8; p < 0.001]. Twenty-three (25%) of 91 case-patients had never received the pentavalent vaccine, and the primary reason cited by caregivers was that they were unaware of any benefits of vaccination. The outbreak is attributable to suboptimal pentavalent vaccination coverage. Future outbreaks may be avoided or their impact reduced through improved risk communication and community engagement on the benefits of vaccination, strengthening routine immunization services, early warning surveillance, and prepositioning of diphtheria antitoxin (DAT) and antibiotics.

PubMedClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026-07-17

Artificial Intelligence Across the Vaccine Clinical Trial Lifecycle: Evidence, Readiness, and Guardrails.

Idriss Jad J, Kalash Suha S, Faraj Jana Abu JA, Nolan Lauren L et al.

Artificial intelligence (AI) is increasingly being used to support clinical research, but its value in vaccine clinical trials requires careful evidence-based assessment. Vaccine trials pose distinctive challenges, including high safety expectations in healthy participants, evolving pathogen exposure and baseline immunity, incomplete correlates of protection, applicability of findings to intended-use populations, and intense public scrutiny. We conducted a structured, vaccine-focused narrative review of AI applications across the vaccine trial lifecycle, supplemented by targeted clinical trial and vaccine pharmacovigilance studies with directly transferable methods. In the combined evidence base, evidence is strongest for operational uses, particularly recruitment, eligibility screening, trial matching, and risk-based monitoring. Applications to immune-response interpretation, correlates of protection, and vaccine safety surveillance are promising but remain less prospectively validated. Responsible adoption should be guided by intended tool use, evidence of strength, data governance, regulatory expectations, and preservation of human scientific and safety judgment.

PubMedIranian journal of nursing and midwifery research2026-07-17

Investigate the Relationship Between Receiving the COVID-19 Vaccine and Menstrual Disorders among Females of Reproductive Age in Jeddah, Saudi Arabia.

Esheaba Ola M OM, Fouly Howieda A HA, Kassem Fathia K FK

There are many physical side effects of the COVID-19 vaccine, including unexpected changes occurring in menstrual bleeding. This study aimed to assess the relation between the COVID-19 vaccine and disorders in menstruation among females of reproductive age. Participants were recruited from a nonprobability snowball sampling targeted at females who are living in Jeddah city between March 2022 and August 2022, Kingdom of Saudi Arabia (KSA). A quantitative cross-sectional design was utilized to conduct the study, a nonexperimental design based on a single observation point. The sample size is estimated by the G*Power software to be 180, considering missed cases, it increased to 197. Regarding menstrual changes, n = 86 (43.65%) experienced a delay, and about one-third reported an earlier menstruation cycle. A significant relationship is observed between nationality, occupation, and changes in period (t = 3.89, P < 0.001 and t = -2.94, P < 0.004). There is no significant difference in the occurrence of complications among the different vaccine types. Receiving the COVID-19 vaccine was strongly linked with unexpected disturbance in menstruation among the studied group, from simple menstrual irregulates to reported amenorrhea after receiving the booster doses. However, the occurrence of menstrual cycle delays was not linked to the vaccine type. Further studies should be done to investigate each type of vaccine specifically to determine if the type of vaccine affects the reproductive function generally not only the menstrual cycle, in a larger survey for more generalizability.

PubMedFrontiers in public health2026-07-17

Reframing vaccine narrative: a co-production study of a media campaign intervention to address childhood vaccine hesitancy among Nigerian parents and caregivers.

Ike Tarela Juliet TJ, Jidong Dung Ezekiel DE, Obi Callistar Kidochukwu CK, Ntaji Maureen Iru MI et al.

Childhood vaccine hesitancy is a public health concern. Nigeria is one of the countries with the highest rates of zero-dose childhood vaccination. This study makes an original contribution by adopting a co-production approach underpinned by interpretative phenomenological analysis (IPA) to meaningfully inform the co-production of a media campaign intervention with Nigerian parents/ caregivers whose child(ren) are not, or only partially, up to date with routine immunizations aimed at reducing childhood vaccine hesitancy and promoting uptake. A total of 10 parents or caregivers whose children were not up to date with their vaccinations were recruited for the study and participated in a focus group discussion. Data were analyzed using IPA. The findings reveal that hostility, misinformation, and the breakdown of trust in vaccines, alongside faith, tradition, and the lived logic of alternative protection, intersect to exacerbate hesitancy. The findings also reveal that clarity, reassurance, and empowerment in vaccine communication, underpinned by gendered voices, can build trust in vaccine messaging and encourage uptake. The study offers important insights for policymakers and public health communication strategies, underscoring the need for culturally appropriate media campaign interventions that address vaccine-related concerns and foster uptake.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about diphtheria vaccine